Gold Bert, Merriam Joanna E, Zernant Jana, Hancox Lisa S, Taiber Andrew J, Gehrs Karen, Cramer Kevin, Neel Julia, Bergeron Julie, Barile Gaetano R, Smith R Theodore, Hageman Gregory S, Dean Michael, Allikmets Rando
Laboratory of Genomic Diversity, National Cancer Institute, Frederick, Maryland 21702, USA.
Nat Genet. 2006 Apr;38(4):458-62. doi: 10.1038/ng1750. Epub 2006 Mar 5.
Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD. Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising approximately 900 individuals with AMD and approximately 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio = 0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.
年龄相关性黄斑变性(AMD)是发达国家中最常见的不可逆性失明形式。编码替代补体途径主要抑制剂的因子H基因(CFH,也称为HF1)中的变异与发生AMD的风险相关。在此,我们检验这样一个假设,即编码同一途径其他调节蛋白的基因变异与AMD相关。我们在两个独立队列中筛查了位于主要组织相容性复合体III类区域的因子B(BF)和补体成分2(C2)基因的遗传变异,这两个队列包括约900例AMD患者和约400例匹配对照。单倍型分析确定了一个具有统计学意义的常见风险单倍型(H1)和两个保护性单倍型。BF的L9H变异和C2的E318D变异(H10),以及C2内含子10中的一个变异和BF的R32Q变异(H7),使AMD风险显著降低(优势比分别为0.45和0.36)。对C2和BF单倍型与CFH变异的联合分析表明,这两个基因座的变异可在74%的受影响个体和56%的对照中预测临床结局。这些数据扩展并完善了我们对AMD遗传风险的认识。